ARTICLE | Clinical News

TT-223: Development discontinued

September 20, 2010 7:00 AM UTC

Transition and partner Eli Lilly discontinued development of TT-223 after a double-blind, placebo-controlled, U.S. Phase Ib trial in about 150 patients showed that the compound in combination with LY2428757, a Phase II pegylated glucagon-like peptide-1 (GLP-1) analog from Lilly that is no longer in development, missed the primary endpoint of significantly reducing HbA1c from baseline to 6 months vs. LY2428757 alone. Patients received placebo or once-daily 2 or 3 mg subcutaneous TT-223 in combination with weekly 14 mg subcutaneous LY2428757 for 4 weeks with a 5 month follow-up period. Eli Lilly licensed exclusive rights to develop and commercialize TT-223 from Transition in 2008 (see BioCentury, March 17, 2008). ...